Evidence map›Paper›PMID 41797988›Full record

ArticleNAR molecular medicine2026

Evaluation of ensilication technology for ambient DNA preservation.

Michael Blas, Celeste Yu, Farnoosh Abbas Aghababazadeh, Vanessa Hoelscher, Marcus Volz, Linden Morales, Kaytee Jarolik, Xiuhua Dong, Sheila Dobin, Tuula Rantasalo and 14 more

Abstract read
In one paragraph

Article in NAR molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Michael BlasCache DNA, Inc. San Carlos, CA 94070,United States.
Celeste YuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada.
Farnoosh Abbas AghababazadehPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada.
Vanessa HoelscherBaylor Scott & White Health, Temple, TX, United States.
Marcus VolzBaylor Scott & White Health, Temple, TX, United States.
Linden MoralesBaylor Scott & White Health, Temple, TX, United States.
Kaytee JarolikBaylor Scott & White Health, Temple, TX, United States.
Xiuhua DongBaylor Scott & White Health, Temple, TX, United States.
Sheila DobinBaylor Scott & White Health, Temple, TX, United States.
Tuula RantasaloGenomill Health Inc., Turku 20520, Finland.
Tatu HirvonenGenomill Health Inc., Turku 20520, Finland.
Juha-Pekka PursiheimoGenomill Health Inc., Turku 20520, Finland.
Nea LaineGenomill Health Inc., Turku 20520, Finland.
Nils HomerFulcrum Genomics LLC, Somerville, MA 02144,United States.
Cassandra ChamounCache DNA, Inc. San Carlos, CA 94070,United States.ORCID https://orcid.org/0000-0003-0440-1971
William PierceCache DNA, Inc. San Carlos, CA 94070,United States.
Lee OrganickCache DNA, Inc. San Carlos, CA 94070,United States.
Adrian FehrCache DNA, Inc. San Carlos, CA 94070,United States.
Michael BecichCache DNA, Inc. San Carlos, CA 94070,United States.
James L BanalCache DNA, Inc. San Carlos, CA 94070,United States.ORCID https://orcid.org/0000-0002-2364-4824
Kenneth YouensBaylor Scott & White Health, Temple, TX, United States.
Manu TamminenGenomill Health Inc., Turku 20520, Finland.
Benjamin Haibe-KainsPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada.
Philippe BedardPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada.ORCID https://orcid.org/0000-0002-6771-2999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current nucleic acid preservation relies on ultra-low temperature storage (-20°C to -80°C), imposing significant infrastructure, cost, and accessibility barriers that limit genomic medicine worldwide. We present a comprehensive evaluation of ensilication, a silica-based encapsulation method enabling ambient-temperature preservation of DNA without compromising sequencing fidelity. Across clinical, genomic, and biochemical analyses, ensilication maintained complete diagnostic concordance with cryogenic controls, detecting all actionable variants in FFPE tumor samples, even at low variant allele frequencies. Whole-genome sequencing revealed that frozen storage accumulated up to 65% more artifactual C>T mutations than ensilicated samples, underscoring its potential to reduce false-positive calls in oncology. Both linear and circular DNA libraries preserved structural integrity across temperatures from -80°C to 37°C. By eliminating cold-chain dependence, ensilication enables decentralized biobanking, point-of-care testing, and equitable access to precision oncology, enabling globally accessible cancer genomics. Its compatibility with emerging sequencing platforms positions ensilication as a foundational technology for next-generation diagnostics and large-scale population studies.

Identifiers

PMID41797988
PMCPMC12961428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.